Restless legs syndrome (Willis-Ekbom disease) is a common sensorimotor disorder defined by an urge to move the legs that appears or worsens at rest, is relieved by movement, and follows a circadian pattern with onset in the evening or night. It is a sleep disorder by consequence rather than by definition - the diagnostic criteria describe a waking sensorimotor experience, but the circadian timing places it at sleep onset, and sleep disruption is what brings most patients to attention. Most patients also show periodic limb movements during sleep, a distinct and separately heritable motor trait. The pathophysiology is not settled. What is best established is regional brain iron deficiency in the presence of normal or near-normal systemic iron stores, most consistently in the substantia nigra, which neuropathology attributes to impaired iron acquisition by neuromelanin-containing cells rather than to degeneration. Around that core sit a dopaminergic abnormality that is a state of relative dopamine excess rather than deficiency, strong non-coding genetic associations at MEIS1 and BTBD9 that connect to iron homeostasis, and candidate adenosinergic and glutamatergic contributions. The therapeutic paradox that shapes management - dopamine agonists work immediately and then cause augmentation, a drug-induced worsening of the disease they treat - follows directly from that unsettled mechanism.
Ask a research question about Restless Legs Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Restless Legs Syndrome
creation_date: "2026-08-24T00:00:00Z"
category: Neurological Disorder
parents:
- Sleep Disorder
- Neurological Disease
disease_term:
preferred_term: restless legs syndrome
term:
id: MONDO:0005391
label: restless legs syndrome
description: >-
Restless legs syndrome (Willis-Ekbom disease) is a common sensorimotor
disorder defined by an urge to move the legs that appears or worsens at rest,
is relieved by movement, and follows a circadian pattern with onset in the
evening or night. It is a sleep disorder by consequence rather than by
definition - the diagnostic criteria describe a waking sensorimotor
experience, but the circadian timing places it at sleep onset, and sleep
disruption is what brings most patients to attention. Most patients also show
periodic limb movements during sleep, a distinct and separately heritable
motor trait. The pathophysiology is not settled. What is best established is
regional brain iron deficiency in the presence of normal or near-normal
systemic iron stores, most consistently in the substantia nigra, which
neuropathology attributes to impaired iron acquisition by
neuromelanin-containing cells rather than to degeneration. Around that core sit a
dopaminergic abnormality that is a state of relative dopamine excess rather
than deficiency, strong non-coding genetic associations at MEIS1 and BTBD9
that connect to iron homeostasis, and candidate adenosinergic and
glutamatergic contributions. The therapeutic paradox that shapes management -
dopamine agonists work immediately and then cause augmentation, a
drug-induced worsening of the disease they treat - follows directly from that
unsettled mechanism.
notes: >-
CURATORIAL POSITION ON THE DOPAMINE STORY. The dopaminergic response is
reliable and the dopaminergic hypothesis is widely repeated, but the direction
usually assumed is wrong: neuropathology and imaging show relative dopamine
EXCESS in the affected regions, and tyrosine hydroxylase staining is normal.
This entry therefore curates the dopaminergic abnormality as a downstream
consequence of brain iron deficiency and as a treatment target, NOT as a
degenerative dopamine deficiency analogous to Parkinson disease. Curators
should not "correct" this toward the familiar deficiency framing - the
augmentation phenomenon is precisely what a deficiency model fails to
predict and an excess-with-receptor-downregulation model does.
The entry deliberately does not conform to
parkinsonism_dopaminergic_degeneration: there is no nigral cell loss here, and
the neuropathology paper cited says so explicitly.
pathophysiology:
- name: Regional Brain Iron Deficiency
description: >-
The best-established abnormality, and the trigger node. Iron content is
reduced in specific brain regions - most consistently the substantia nigra,
also the thalamus - while systemic iron stores may be entirely normal. This
is a compartment-specific deficiency, not a systemic one, which is why serum
ferritin is an unreliable guide and why oral iron is ineffective in
iron-sufficient patients. Neuropathologically the lesion is one of acquisition
rather than of loss: H-ferritin and iron staining are markedly reduced,
transferrin receptor staining on neuromelanin-containing cells is decreased
while transferrin itself is increased - the signature of cells that are iron
starved but failing to upregulate their uptake machinery, i.e. a regulatory
defect at the transferrin receptor. Crucially there is no neurodegeneration:
the RLS brain shows no histopathological abnormality unique to it and normal
tyrosine hydroxylase staining, which distinguishes this disorder from the
dopaminergic degenerations at the level of tissue.
role: trigger
biological_scale: CELLULAR
biological_processes:
- preferred_term: iron ion transport
term:
id: GO:0006826
label: iron ion transport
modifier: DECREASED
locations:
- preferred_term: substantia nigra
term:
id: UBERON:0002038
label: substantia nigra
evidence:
- reference: PMID:12913188
reference_title: Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Iron staining and H-ferritin staining was markedly decreased in the RLS
substantia nigra.
explanation: >-
Direct neuropathological demonstration of the regional iron deficit that
this node asserts.
- reference: PMID:12913188
reference_title: Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
RLS may not be rooted in pathologies associated with traditional
neurodegenerative processes but may be a functional disorder resulting from
impaired iron acquisition by the neuromelanin cells in RLS. The underlying
mechanism may be a defect in regulation of the transferrin receptors.
explanation: >-
Establishes both halves of the node's claim - that the lesion is impaired
acquisition rather than degeneration, and that the defect is at the level
of transferrin receptor regulation.
- reference: PMID:12913188
reference_title: Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
There were no histopathologic abnormalities unique to the RLS brains.
Tyrosine hydroxylase staining in the major dopaminergic regions appeared
normal in the RLS brains.
explanation: >-
The negative finding that keeps this entry out of the dopaminergic
degeneration family, and the reason the notes forbid recurating the
dopaminergic node as a deficiency.
downstream:
- target: Altered Dopaminergic Signalling with Relative Dopamine Excess
description: >-
Iron is the cofactor of tyrosine hydroxylase and is required for normal
dopamine receptor and transporter regulation, so regional iron deficiency
perturbs dopaminergic signalling in the same regions.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- target: Sensorimotor Network Hyperexcitability
description: >-
Brain iron deficiency is also proposed to reduce adenosinergic tone and
raise glutamatergic transmission, contributing to hyperexcitability
independently of the dopaminergic arm.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Genetic Susceptibility at Iron-Linked Regulatory Loci
description: >-
Restless legs syndrome is highly heritable, and its common risk variants are
unusual in two respects that are mechanistically informative. First, they are
almost all non-coding and regulatory rather than protein-altering - the
strongest signal is a linkage-disequilibrium block within intron 8 of MEIS1 -
so the disease mechanism runs through altered expression of developmental
transcription factors, not through altered protein function. Second, the
effect sizes are among the largest reported for any common disease, and yet
identified variants explain under 10% of heritability. MEIS1 risk haplotype
carriers show lower MEIS1 mRNA and protein in blood and thalamus, and the
MEIS1 orthologue is linked to iron homeostasis in C. elegans - which is the
connection that ties the genetic arm back to the iron trigger rather than
leaving it a separate story.
role: trigger
biological_scale: MOLECULAR
evidence:
- reference: PMID:17637780
reference_title: Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In a genome-wide association study we found highly significant associations
between RLS and intronic variants in the homeobox gene MEIS1, the BTBD9
gene encoding a BTB(POZ) domain as well as variants in a third locus
containing the genes encoding mitogen-activated protein kinase MAP2K5 and
the transcription factor LBXCOR1
explanation: >-
The founding association study, identifying the three loci this node
encodes and establishing that they are intronic rather than coding.
- reference: PMID:17637780
reference_title: Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Each genetic variant was associated with a more than 50% increase in risk
for RLS, with the combined allelic variants conferring more than half of
the risk.
explanation: >-
Quantifies the unusually large common-variant effect sizes referred to in
the node description.
- reference: PMID:31551905
reference_title: "MEIS1 and Restless Legs Syndrome: A Comprehensive Review."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Work in C. elegans showed a link between the MEIS1 ortholog and iron
homeostasis, which is in line with the fact that central nervous system
(CNS) iron insufficiency is thought to be a cause of RLS.
explanation: >-
The link that connects the genetic trigger to the iron trigger, and the
reason both are curated as arms of one disorder rather than as competing
accounts.
- reference: PMID:31551905
reference_title: "MEIS1 and Restless Legs Syndrome: A Comprehensive Review."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
The genetic factors so far identified explain less than 10% of the disease
heritability.
explanation: >-
Cited as PARTIAL because it bounds the genetic arm rather than supporting
it: the associations are real and strong but account for a small fraction
of a highly heritable disorder, so this node cannot be presented as the
cause.
downstream:
- target: Regional Brain Iron Deficiency
description: >-
Risk-haplotype-associated reduction in MEIS1 expression is proposed to act
through iron homeostasis, though the specific protein function linking the
two has not been established.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Altered Dopaminergic Signalling with Relative Dopamine Excess
description: >-
The dopaminergic abnormality, curated in the direction the evidence
supports. The iron-deficient regions show a state of relative dopamine
excess, not deficiency, with presynaptic upregulation and postsynaptic
receptor downregulation; tyrosine hydroxylase staining is normal and there is
no cell loss. This reading is what makes sense of the disorder's two most
distinctive pharmacological facts. Dopamine agonists relieve symptoms
immediately, at doses far below those used in Parkinson disease, because they
act on a downregulated postsynaptic system at its circadian trough. And
sustained agonist exposure produces augmentation - earlier onset, greater
intensity, and spread to the arms - which is what a chronically overdriven
system that is already in relative excess would be expected to do, and which a
deficiency model does not predict at all.
role: amplifier
biological_scale: CELLULAR
biological_processes:
- preferred_term: dopaminergic synaptic transmission
term:
id: GO:0001963
label: synaptic transmission, dopaminergic
modifier: ABNORMAL
locations:
- preferred_term: substantia nigra
term:
id: UBERON:0002038
label: substantia nigra
evidence:
- reference: PMID:28236139
reference_title: "Iron, dopamine, genetics, and hormones in the pathophysiology of restless legs syndrome."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Human neuropathologic and imaging studies have consistently shown decreased
iron in different brain regions including substantia nigra and thalamus.
These same areas also demonstrate a state of relative dopamine excess.
explanation: >-
States the direction of the dopaminergic abnormality explicitly and
co-localises it with the iron deficit, which is the whole basis for
curating this node downstream of iron rather than as an independent
deficiency.
- reference: PMID:28236139
reference_title: "Iron, dopamine, genetics, and hormones in the pathophysiology of restless legs syndrome."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
While it is not known how these changes in dopamine or iron produce the
symptoms of RLS
explanation: >-
Cited as PARTIAL because it records the limit of the account: the
iron-dopamine relationship is established but the step from it to the
sensory symptom is not, which is why the downstream edge is curated with
unknown intermediates.
downstream:
- target: Sensorimotor Network Hyperexcitability
description: >-
Altered dopaminergic modulation of spinal and supraspinal sensorimotor
circuits is proposed to lower the threshold for the sensory urge and for
periodic limb movements, though the intervening steps are unknown.
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Sensorimotor Network Hyperexcitability
description: >-
The convergence node: a state of increased excitability in spinal and
supraspinal sensorimotor circuits, expressed as an aversive sensory urge at
rest and as involuntary periodic limb movements during sleep. Beyond the
dopaminergic arm, the leading candidate contributors are reduced adenosinergic
tone (adenosine is inhibitory, and brain iron deficiency has been proposed to
downregulate A1 receptors) and increased glutamatergic transmission - which
would explain why alpha-2-delta ligands, which reduce glutamate release and
have no dopaminergic action at all, are as effective as dopamine agonists.
That equivalence is a strong constraint on any mechanistic account, and it is
the reason this node is curated as a convergence point rather than as a
dopaminergic effector.
role: central_effector
biological_scale: CELLULAR
biological_processes:
- preferred_term: glutamatergic synaptic transmission
term:
id: GO:0035249
label: synaptic transmission, glutamatergic
modifier: INCREASED
evidence:
- reference: PMID:34732752
reference_title: Restless legs syndrome.
supports: SUPPORT
evidence_source: OTHER
snippet: >-
The pathophysiology is still unclear, with the involvement of brain iron
deficiency, dysfunction in the dopaminergic and nociceptive systems and
altered adenosine and glutamatergic pathways as hypotheses being
investigated.
explanation: >-
Cited as PARTIAL because it is the disease primer's own statement that the
pathophysiology is unresolved and that the adenosinergic and glutamatergic
contributions are hypotheses under investigation, not established
mechanism - the calibration this node is written to preserve.
- reference: PMID:28888061
reference_title: "Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Network meta-analysis of mean changes in IRLS data from 35 studies with
7333 participants showed that all treatments, in specific gabapentin
enacarbil, followed by pregabalin and rotigotine were superior to placebo
explanation: >-
The meta-analytic finding itself: two alpha-2-delta ligands and a dopamine
agonist all beat placebo, with the alpha-2-delta ligands leading. Since the
alpha-2-delta ligands have no dopaminergic action, their equivalence is the
pharmacological constraint requiring a convergence node here rather than a
purely dopaminergic effector.
downstream:
- target: Rest-Dependent Urge to Move with Circadian Timing
description: >-
Hyperexcitable sensorimotor circuits produce the characteristic sensory
urge when sensory input and motor output are reduced by rest.
causal_link_type: DIRECT
- target: Periodic Limb Movements of Sleep
description: >-
The same hyperexcitability, expressed through spinal motor circuits
released during sleep, produces stereotyped periodic movements.
causal_link_type: DIRECT
- name: Rest-Dependent Urge to Move with Circadian Timing
description: >-
The defining clinical phenomenon, and its two modulations are diagnostic
rather than incidental. It is rest-dependent: the urge appears during
inactivity and is relieved, immediately and completely, by movement - a
relief pattern no other sensory symptom shares. And it is circadian:
symptoms appear in the evening and night, following the endogenous rhythm
rather than time awake, which is why they persist at the same clock time
after a shifted schedule and why sleep onset is the point of maximal
impairment.
role: effector
biological_scale: ORGANISM
biological_processes:
- preferred_term: circadian rhythm
term:
id: GO:0007623
label: circadian rhythm
evidence:
- reference: PMID:34732752
reference_title: Restless legs syndrome.
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Restless legs syndrome (RLS) is a common sensorimotor disorder
characterized by an urge to move that appears during rest or is exacerbated
by rest, that occurs in the evening or night and that disappears during
movement or is improved by movement.
explanation: >-
Gives all three defining features of this node - rest dependence,
circadian timing, and relief by movement - in the primer's own definition.
downstream:
- target: Sleep Disruption and Its Consequences
description: >-
Symptoms peaking at the time of intended sleep onset delay and fragment
sleep.
causal_link_type: DIRECT
- name: Periodic Limb Movements of Sleep
description: >-
Stereotyped, repetitive limb movements during sleep, present in most patients
with restless legs syndrome and quantifiable on polysomnography. Curated as
its own node because the genetics show it is partly separable: the BTBD9
variant is associated with periodic limb movements both with and without the
restless legs phenotype, and NOT with restless legs in the absence of
periodic limb movements - which identifies it as a genetic determinant of the
movement trait rather than of the sensory disorder. Treating the two as one
entity would discard that dissociation.
role: effector
biological_scale: ORGANISM
evidence:
- reference: PMID:17634447
reference_title: A genetic risk factor for periodic limb movements in sleep.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
An association between the variant and periodic limb movements in sleep
without RLS (and the absence of such an association for RLS without
periodic limb movements) suggests that we have identified a genetic
determinant of periodic limb movements in sleep
explanation: >-
The dissociation evidence that justifies curating periodic limb movements
as a separate node rather than as a feature of the sensory disorder.
- reference: PMID:17634447
reference_title: A genetic risk factor for periodic limb movements in sleep.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Serum ferritin levels were decreased by 13% per allele of the at-risk
variant
explanation: >-
Ties this node's genetic determinant back to iron status quantitatively,
which is the link between the movement trait and the module's trigger.
downstream:
- target: Sleep Disruption and Its Consequences
description: >-
Repetitive movements, particularly when associated with cortical arousals,
fragment sleep.
causal_link_type: DIRECT
- name: Sleep Disruption and Its Consequences
description: >-
The clinical endpoint through which restless legs syndrome becomes a sleep
disorder: delayed sleep onset from the evening urge, fragmentation from
periodic movements, and consequent daytime impairment and mood disturbance.
Severity varies widely, and only the more severe forms warrant drug
treatment - a threshold that matters here more than in most disorders,
because the most effective first-line agents carry augmentation risk.
role: consequence
biological_scale: ORGANISM
biological_processes:
- preferred_term: sleep
term:
id: GO:0030431
label: sleep
modifier: ABNORMAL
evidence:
- reference: PMID:34732752
reference_title: Restless legs syndrome.
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Symptoms vary considerably in age at onset, frequency and severity, with
severe forms affecting sleep, quality of life and mood.
explanation: >-
Establishes both the sleep and mood consequences and the wide severity
distribution that governs the treatment threshold.
phenotypes:
- category: Neurological
name: Urge to Move the Legs at Rest
description: >-
An uncomfortable urge to move the legs, beginning or worsening during
inactivity and relieved by movement. The defining criterion of the disorder.
phenotype_term:
preferred_term: Restless legs
term:
id: HP:0012452
label: Restless legs
temporality: NOCTURNAL
frequency: OBLIGATE
evidence:
- reference: PMID:34732752
reference_title: Restless legs syndrome.
supports: SUPPORT
evidence_source: OTHER
snippet: >-
characterized by an urge to move that appears during rest or is exacerbated
by rest, that occurs in the evening or night and that disappears during
movement or is improved by movement
explanation: >-
OBLIGATE by definition rather than by observation: this is the diagnostic
criterion, so every diagnosed patient has it.
- category: Neurological
name: Periodic Limb Movements of Sleep
description: >-
Stereotyped repetitive limb movements during sleep or resting wakefulness,
detectable on polysomnography and present in most but not all patients.
phenotype_term:
preferred_term: Periodic limb movements of sleep
term:
id: HP:5200295
label: Periodic limb movements of sleep
frequency: FREQUENT
evidence:
- reference: PMID:34732752
reference_title: Restless legs syndrome.
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Patients with RLS often display periodic leg movements during sleep or
resting wakefulness.
explanation: >-
"Often" in the disease primer maps to the FREQUENT band (roughly 30-79%);
a higher band is not supported by this source and is not asserted.
- category: Neurological
name: Sleep Disturbance
description: >-
Delayed sleep onset and fragmented sleep, driven by the evening peak of
symptoms and by periodic limb movements. The commonest reason patients
present.
phenotype_term:
preferred_term: Sleep disturbance
term:
id: HP:0002360
label: Sleep disturbance
temporality: CHRONIC
evidence:
- reference: PMID:17634447
reference_title: A genetic risk factor for periodic limb movements in sleep.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It is a major cause of sleep disruption.
explanation: >-
Supports sleep disruption as a core consequence; no frequency band is
asserted, since the source does not quantify it.
genetic:
- name: MEIS1
notes: >-
The strongest common-variant association in restless legs syndrome and one of
the strongest reported for any common disease. Risk variants are non-coding,
concentrated in a linkage-disequilibrium block in intron 8, and act by
reducing MEIS1 expression rather than by altering the protein. Carriers of
the risk haplotype show lower MEIS1 mRNA and protein in blood and thalamus.
gene_term:
preferred_term: MEIS1
term:
id: hgnc:7000
label: MEIS1
relationship_type: SUSCEPTIBILITY
evidence:
- reference: PMID:31551905
reference_title: "MEIS1 and Restless Legs Syndrome: A Comprehensive Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
this gene shows a lower expression of mRNA and protein in blood and
thalamus of individuals with the MEIS1 RLS risk haplotype
explanation: >-
Establishes the direction of effect - reduced expression - which is what
makes this a regulatory rather than a coding mechanism.
- reference: PMID:31551905
reference_title: "MEIS1 and Restless Legs Syndrome: A Comprehensive Review."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
The MEIS1 GWAS signals are some of the strongest genetic associations
reported for any common disease.
explanation: >-
Records the unusual effect size that distinguishes this association from a
typical common-disease signal.
- name: BTBD9
notes: >-
A common intronic variant at BTBD9 confers susceptibility, and the genetics
identify it specifically as a determinant of periodic limb movements in
sleep rather than of the restless legs sensory phenotype. The at-risk allele
also lowers serum ferritin, connecting the locus to iron status.
gene_term:
preferred_term: BTBD9
term:
id: hgnc:21228
label: BTBD9
relationship_type: SUSCEPTIBILITY
evidence:
- reference: PMID:17634447
reference_title: A genetic risk factor for periodic limb movements in sleep.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
we observed a genomewide significant association with a common variant in
an intron of BTBD9 on chromosome 6p21.2
explanation: >-
The primary association finding for this locus.
- reference: PMID:17634447
reference_title: A genetic risk factor for periodic limb movements in sleep.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
With this variant, the population attributable risk of RLS with periodic
limb movements was approximately 50%.
explanation: >-
Quantifies the population impact of the locus in the phenotype it is
specific to.
inheritance:
- name: Complex/Multifactorial
inheritance_term:
preferred_term: Polygenic inheritance
term:
id: HP:0010982
label: Polygenic inheritance
description: >-
Highly heritable but not Mendelian: twin and familial aggregation studies
place heritability at roughly 54-69%, while identified common variants
explain under 10% of it. Linkage studies in large multiplex families
identified loci but no causative variant, and results were often not
reproducible - which is why the field moved to association study designs.
evidence:
- reference: PMID:31551905
reference_title: "MEIS1 and Restless Legs Syndrome: A Comprehensive Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Twin studies and a familial aggregation analysis estimated the heritability
of RLS between 54.0 and 69.4%, thus there is a strong genetic element to
the disease
explanation: >-
Quantifies heritability, establishing a strong genetic contribution
without a Mendelian architecture.
treatments:
- name: Intravenous Ferric Carboxymaltose
description: >-
Iron repletion is the only treatment directed at the entry's trigger node
rather than at its downstream consequences, and it is the mechanistically
most interesting: a single intravenous dose can produce prolonged benefit,
consistent with correcting a compartment rather than maintaining a drug
level. Two caveats are curated deliberately. The effect is slow - in a
randomised trial in iron-deficient non-anaemic patients the difference from
placebo was not significant at 4 weeks and became significant only by 12
weeks - which means a 4-week endpoint will call it a failure. And oral iron
is not a substitute: it is non-efficacious in iron-sufficient patients, which
is what a compartment-specific rather than systemic deficiency predicts.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: ferric carboxymaltose
term:
id: NCIT:C166915
label: Ferric Carboxymaltose
target_mechanisms:
- target: Regional Brain Iron Deficiency
treatment_effect: INHIBITS
description: >-
Parenteral iron raises the iron available for central uptake, addressing
the trigger node directly rather than modulating downstream signalling.
evidence:
- reference: PMID:28643901
reference_title: "Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Ferric carboxymaltose treatment (n = 59) led to nonsignificant improvement
over placebo (n = 51) in International Restless Legs Syndrome Severity Scale
score at week 4
explanation: >-
Cited as PARTIAL and deliberately: the primary endpoint was negative. The
benefit emerged only at the secondary 12-week timepoint, so the evidence
supports a delayed effect rather than an established one.
- reference: PMID:29756335
reference_title: "Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Intravenous ferric carboxymaltose and pneumatic compression devices are
considered likely efficacious in idiopathic restless legs syndrome.
explanation: >-
The evidence-based review's own grading - "likely efficacious" rather than
"efficacious" - which is the calibration this treatment is curated at.
- reference: PMID:29756335
reference_title: "Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Oral iron is nonefficacious in iron-sufficient subjects, but its benefit for
patients with low peripheral iron status has not been adequately evaluated.
explanation: >-
Supports the distinction between routes of iron repletion, and is
consistent with the trigger node being a compartment-specific rather than
systemic deficiency.
- name: Alpha-2-Delta Ligand (Gabapentin Enacarbil, Pregabalin)
description: >-
Ligands of the alpha-2-delta subunit of the voltage-gated calcium channel,
which reduce presynaptic neurotransmitter release including glutamate. They
are as effective as a dopamine agonist in head-to-head meta-analysis while
carrying substantially less augmentation risk, and are increasingly
preferred first-line for that reason. Their efficacy is also the strongest
single argument that the disorder's effector node is not purely
dopaminergic - a drug with no dopaminergic action should not work as well as
one that has it, if the mechanism were dopaminergic.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: gabapentin enacarbil
term:
id: CHEBI:68840
label: gabapentin enacarbil
target_mechanisms:
- target: Sensorimotor Network Hyperexcitability
treatment_effect: INHIBITS
description: >-
Reduces presynaptic calcium-dependent neurotransmitter release, damping the
hyperexcitable sensorimotor state without acting on dopaminergic
transmission.
evidence:
- reference: PMID:29756335
reference_title: "Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Pregabalin, gabapentin enacarbil, and oxycodone/naloxone, which did not
appear in the previous review, have accrued data to be considered
efficacious.
explanation: >-
Evidence-based review grading of the alpha-2-delta ligands as efficacious,
the highest tier the review assigns.
- name: Dopamine Agonist (Pramipexole)
description: >-
Immediately and reliably effective at doses well below those used in
Parkinson disease, and for many years first-line - but curated here with its
principal harm attached, because the harm is mechanistically informative
rather than incidental. Sustained dopaminergic treatment causes augmentation:
the disease itself worsens, with symptoms starting earlier in the day,
becoming more intense, and spreading to previously unaffected limbs. The
evidence-based review identifies augmentation as more frequent with
pramipexole than pregabalin and possibly with all dopaminergic agents more
than alpha-2-delta ligands, and requires special monitoring for every
dopaminergic drug. A treatment that reverses into an exacerbation of the
disorder is exactly what a relative-dopamine-excess model predicts and a
deficiency model does not.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: pramipexole
term:
id: CHEBI:8356
label: pramipexole
target_mechanisms:
- target: Altered Dopaminergic Signalling with Relative Dopamine Excess
treatment_effect: ACTIVATES
description: >-
Postsynaptic dopamine receptor agonism relieves symptoms acutely; sustained
agonism at the same node is what drives augmentation, so the therapeutic
and adverse effects share a target.
evidence:
- reference: PMID:29756335
reference_title: "Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
The following interventions continue to be considered efficacious as in
2008: levodopa, ropinirole, pramipexole, cabergoline, pergolide, and
gabapentin.
explanation: >-
Establishes efficacy at the review's highest grading.
- reference: PMID:29756335
reference_title: "Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)."
supports: REFUTE
evidence_source: OTHER
snippet: >-
Restless legs syndrome augmentation has been identified as a significant
long-term treatment complication for pramipexole more than pregabalin
explanation: >-
Cited as REFUTE against the claim that dopaminergic therapy is a durable
solution: the same review that grades it efficacious identifies
augmentation as a significant long-term complication, differentially worse
for the dopamine agonist than for the alpha-2-delta comparator.
- reference: PMID:34732752
reference_title: Restless legs syndrome.
supports: REFUTE
evidence_source: OTHER
snippet: >-
Although dopaminergic treatment is initially highly effective, its
long-term use can result in a serious worsening of symptoms known as
augmentation.
explanation: >-
The disease primer's independent statement of the same reversal, recorded
so that the acute efficacy above cannot be curated without it.
prevalence:
- population: Adult population, minimum IRLSSG diagnostic criteria, European and North American
measure_type: POINT_PREVALENCE
prevalence_class: ABOVE_1_IN_1000
rate_low: 3900.0
rate_high: 14300.0
notes: >-
A wide range reflecting the use of minimum criteria without a severity or
frequency threshold; the proportion with clinically significant disease
warranting treatment is substantially smaller. More common in women, and
prevalence rises with age.
evidence:
- reference: PMID:31551905
reference_title: "MEIS1 and Restless Legs Syndrome: A Comprehensive Review."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
The prevalence of RLS cases based on the minimum diagnostic criteria of the
international RLS study group (IRLSSG) was estimated between 3.9 and 14.3%
of the adult population.
explanation: >-
Gives the range and states the ascertainment basis (minimum criteria),
which is what the note qualifies.
classifications:
harrisons_chapter:
- classification_value: NEUROLOGIC
evidence:
- reference: PMID:34732752
reference_title: Restless legs syndrome.
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Restless legs syndrome (RLS) is a common sensorimotor disorder
explanation: >-
A sensorimotor neurological disorder; classified under the nervous-system
chapter, the schema having no dedicated sleep chapter.
discussions:
- discussion_id: gap_augmentation_mechanism
kind: KNOWLEDGE_GAP
prompt: >-
What is the mechanism of dopaminergic augmentation, and can it be predicted
or prevented?
attaches_to:
- pathophysiology#Altered Dopaminergic Signalling with Relative Dopamine Excess
rationale: >-
Augmentation is the central clinical problem of this disorder and one of the
few examples in medicine of a treatment reliably converting into an
exacerbation of the disease it treats. It is the strongest available probe
of the dopaminergic node: a deficiency model has no account of it, while an
excess-plus-receptor-downregulation model predicts it, so establishing its
mechanism would settle the direction of the dopaminergic abnormality.
Practically, there is no way to identify in advance which patients will
augment, and by the time it appears the dopaminergic agent is difficult to
withdraw. Low iron status is a suspected risk factor, which - if confirmed -
would tie augmentation risk back to the trigger node and make iron repletion
a preventive as well as a therapeutic intervention.
proposed_experiments:
- experiment_id: exp_augmentation_iron_stratified_cohort
name: Iron-stratified prospective cohort of dopaminergic initiation
description: >-
Prospective follow-up of treatment-naive patients starting a dopamine
agonist, stratified at baseline by peripheral iron status and, where
feasible, by brain iron on quantitative susceptibility MRI, with augmentation
as the outcome; testing whether the trigger node's severity predicts the
complication and whether prior iron repletion reduces its incidence.
- discussion_id: gap_iron_to_symptom_step
kind: KNOWLEDGE_GAP
prompt: >-
How does regional brain iron deficiency produce a rest-dependent, circadian
sensory urge?
attaches_to:
- pathophysiology#Regional Brain Iron Deficiency
- pathophysiology#Sensorimotor Network Hyperexcitability
rationale: >-
The two ends of this entry's causal chain are each well supported and the
middle is not: the iron deficit is demonstrated neuropathologically and the
clinical phenomenology is precisely characterised, but the step between them
is explicitly unknown, which is why the downstream edges here carry unknown
intermediates. Two features of the symptom are especially unexplained by an
iron-and-dopamine account. Its circadian timing follows endogenous phase
rather than time awake, implicating an interaction with the circadian system
that neither the iron nor the dopamine arm addresses; and its immediate,
complete relief by voluntary movement implies a sensorimotor gating
mechanism rather than a static excitability change.
proposed_experiments:
- experiment_id: exp_forced_desynchrony_rls_symptom_timing
name: Forced desynchrony of restless legs symptom timing
description: >-
A forced-desynchrony protocol dissociating circadian phase from time
awake in patients with restless legs syndrome, with symptom intensity and
periodic limb movement rate as outcomes, to establish which of the two the
symptom rhythm follows and whether iron status modifies the amplitude of
that rhythm.